Shockwave Medical Completes Acquisition of Neovasc
Santa Clara, California--(Newsfile Corp. - April 11, 2023) - Shockwave Medical, Inc. (NASDAQ: SWAV) ("Shockwave"), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced the completion of its previously announced acquisition of Neovasc Inc. ("Neovasc").The Neovasc Reducer System (the "Reducer") is a first-of-its-kind technology to address refractory angina. Refractory angina is a chronic condition in which a patient...
2023-04-11 8:18 AM EDT
Neovasc Shareholders Approve Acquisition by Shockwave Medical
Vancouver, British Columbia--(Newsfile Corp. - March 6, 2023) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive devices for the treatment of refractory angina, is pleased to announce that its Shareholders (as defined below) have approved the previously-announced acquisition of all of the outstanding common shares of the Company (the "Shares") by Shockwave Medical, Inc. ("Shockwave") by way of a statutory plan of...
2023-03-06 6:00 PM EST
Neovasc Announces German Reimbursement Renewal
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - February 1, 2023) - Neovasc, Inc. (NASDAQ : NVCN) (TSX : NVCN) ("Neovasc" or "the Company") today announced the German Institute for the Hospital Remuneration System ("InEK") has awarded the Neovasc Reducer™ ("Reducer"), a CE-Marked medical device for the treatment of refractory angina, NUB Status 1 designation for 2023.New examination and treatment methods (NUBs) are comprised of novel and innovative medicines, medical products...
2023-02-01 9:05 AM EST
Shockwave Medical to Acquire Neovasc
Vancouver, British Columbia--(Newsfile Corp. - January 17, 2023) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive devices for the treatment of refractory angina, announced today that the Company has entered into a binding agreement (the "Arrangement Agreement") with Shockwave Medical, Inc. ("Shockwave"), whereby Shockwave has agreed to acquire all of the issued and outstanding common shares (the "Common Shares") of the...
2023-01-17 8:27 AM EST
Neovasc Announces Progress on COSIRA-II Clinical Trial
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 28, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced an update on the COSIRA-II Clinical Trial ("Trial") status. COSIRA-II is the U.S. Investigational Device Exemption ("IDE") pivotal clinical trial the Company is executing for the Neovasc Reducer™ ("Reducer") towards an approval decision for the device in the United States. The Trial will randomize approximately 380 patients at...
2022-11-28 5:00 PM EST
Neovasc Comments on European Heart Journal Publication
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 18, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that European Heart Journal - Case Reports has published an article titled, "Implantation of the Coronary Sinus Reducer for Refractory Angina due to Coronary Microvascular Dysfunction in the Context of Apical Hypertrophic Cardiomyopathy - a Case Report." The article is authored by Dr. Kevin Cheng, et al, at the National Heart...
2022-11-18 9:05 AM EST
Neovasc Announces Third Quarter Financial Results and Provides Corporate Update
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 10, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today reported financial results for the third quarter ended September 30, 2022.Recent HighlightsGenerated revenues of $923,000, a quarterly record and a year-over-year increase of 31% compared to the third quarter of 2021.Accelerating acceptance of Reducer in the UK and French markets, with France the largest volume market in the...
2022-11-10 4:05 PM EST
Neovasc Reducer Obtains U.S. Outpatient Reimbursement
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 8, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that the Centers for Medicare and Medicaid Services ("CMS") has assigned the Neovasc Reducer™ ("Reducer") implant procedure a new outpatient reimbursement code payment status indicator, enabling U.S. hospitals to be reimbursed for the device and implant procedure.Effective January 1, 2023, the implantation of the Reducer in an...
2022-11-08 9:05 AM EST
Neovasc to Report Third Quarter Financial Results on November 10, 2022
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - October 27, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) will report financial results for the quarter ended September 30, 2022 on Thursday, November 10, 2022. Neovasc's President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review the company's results at 4:30 pm ET on November 10, 2022.Interested parties may access the conference call by dialing (800)...
2022-10-27 9:00 AM EDT
Neovasc Provides Corporate Update Following Clinical Data Release
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - September 20, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced positive clinical data at the Transcatheter Cardiovascular Therapeutics Conference ("TCT") held September 16-19 in Boston.Prof. Shmuel Banai, MD, Neovasc Medical Director and Head of Interventional Cardiology at the Tel Aviv Medical Center, Israel, presented new interim clinical data on the use of the Neovasc Reducer™ ("Reducer")...
2022-09-20 9:05 AM EDT
Neovasc to Participate in LSI Europe 2022 Emerging MedTech Summit
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - September 16, 2022) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) (Neovasc or the Company) today announced that its management team will be participating in the LSI Europe 2022 Emerging MedTech Summit in Hertfordshire, United Kingdom on September 21-24, 2022.Neovasc's President and Chief Executive Officer, Fred Colen, will be presenting at 11:10 am BST / 6:10 am ET on September 23, 2022. Interested parties may view a live stream of...
2022-09-16 9:00 AM EDT
Neovasc Comments on New ICD-10-CM Diagnosis Codes for Refractory Angina
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - September 15, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today commented on the Centers for Medicare and Medicaid Services ("CMS") development of new codes for the diagnosis and tracking of refractory angina. The new codes will be utilized in the current, 10th revision of the International Statistical Classification of Diseases and Related Health Problems Clinical Modification ("ICD-10-CM"). The...
2022-09-15 9:05 AM EDT
Neovasc Announces Key Events at TCT 2022
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - September 8, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced its participation and presence at the Transcatheter Cardiovascular Therapeutics TCT 2022 conference ("TCT"), hosted by the Cardiovascular Research Foundation ("CRF"), taking place in person at the Boston Convention & Exhibition Center, September 16-19, 2022. Members of the Neovasc team will be available at booth 647 in the...
2022-09-08 9:05 AM EDT
Neovasc to Participate in H.C. Wainwright 24th Annual Global Investment Conference
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - August 30, 2022) - Neovasc, Inc. (Neovasc or the Company) (NASDAQ: NVCN) (TSX: NVCN) today announced that its management team will be participating in the H.C. Wainwright 24th Annual Global Investment Conference to be held September 12-14, 2022, in New York City. Neovasc's President and Chief Executive Officer, Fred Colen, will be presenting at 1:30 pm ET on Tuesday, September 13, 2022. A live webcast of the presentation can be...
2022-08-30 9:05 AM EDT
Neovasc Announces Second Quarter Financial Results and Provides Corporate Update
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - August 11, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today reported financial results for the second quarter ended June 30, 2022.Recent HighlightsGenerated revenues of $818,000, a quarterly record and a year-over-year increase of 29% over the second quarter of 2021.Advanced enrollment in the COSIRA II trial with 40 patients enrolled and 21 patients randomized across 10 sites.COSIRA II protocol...
2022-08-11 4:05 PM EDT
Neovasc to Report Second Quarter Financial Results on August 11, 2022
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - July 28, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN), will report financial results for the quarter ended June 30, 2022 on Thursday, August 11, 2022. Neovasc's President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review the company's results at 4:30 pm EDT on August 11, 2022.Interested parties may access the conference call by dialing (877) 407-9208 or (201)...
2022-07-28 9:00 AM EDT
Neovasc Announces FDA Approval of Planned COSIRA II Sub-studies and Single Arm Registry to Allow Inclusion of Additional Specified Patient Populations
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - July 26, 2022) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced the United States Food and Drug Administration ("FDA") has approved a protocol supplement to the COSIRA-II Investigational Device Exemption ("IDE") Trial. The approval expands the number of patients eligible for treatment in the trial and adds two previously planned imaging sub-studies designed to provide insights into the safety...
2022-07-26 9:05 AM EDT
Neovasc Announces Direct Sales Operations in United Kingdom
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - July 5, 2022) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that the company has expanded its direct sales operations in Europe to include the United Kingdom, effective July 1, 2022. The company has hired its first two direct employees in England and plans future growth in the sales team as the commercial requirements increase.The decision to move to a direct sales operation in the U.K....
2022-07-05 9:05 AM EDT
Neovasc to Participate in Sidoti & Co. Summer Small Cap Virtual Investor Conference
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - June 8, 2022) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) (Neovasc or the Company) today announced that its management team will be participating in the 2022 Sidoti & Co. Summer Small Cap Virtual Investor Conference to be held June 15-16, 2022. Neovasc's Chief Operating Officer, Bill Little, will be presenting at 1:45 pm ET on Wednesday, June 15.The presentation can be accessed here. Additionally, a recording of the presentation...
2022-06-08 9:05 AM EDT
Neovasc to Participate in H.C. Wainwright Global Investment Conference
British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - May 23, 2022) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) (Neovasc or the Company) today announced that its management team will be participating in the H.C. Wainwright Global Investment Conference to be held May 23-26, 2022. Fred Colen, Neovasc's President and Chief Executive Officer, will be presenting at 11:00 am ET on Wednesday, May 25. A live webcast of Mr. Colen's presentation can be accessed using the link available in the...
2022-05-23 4:05 PM EDT